PERSONALIZED TREATMENT OF OPHTHALMOLOGIC DISEASES

• Main Authors: OSBORNE Aaron, LIN Hugh, WILLIS Jeffrey R, SILVERMAN David Andrew, WEIKERT Robert James
• Format: Patent
• Language: English; Spanish
• Published: 22.02.2022
• Subjects: CHEMISTRY; HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATIONTECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING ORPROCESSING OF MEDICAL OR HEALTHCARE DATA; HUMAN NECESSITIES; HYGIENE; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The current invention relates to antibodies which bind to VEGF and ANG2 for use in the treatment of ocular vascular diseases such as neovascular AMD (nAMD) (also known as choroidal neovascularization [CNV] secondary to age-related macular degeneration [AMD] or wet AMD), diabetic retinopathy in particular diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion (RVO). La presente invención se refiere a anticuerpos que se unen a VEGF y ANG2 para su uso en el tratamiento de enfermedades vasculares oculares, tales como AMD neovascular (nAMD) (también conocida como neovascularización coroidea [CNV] secundaria a la degeneración macular relacionada con la edad [AMD] o AMD húmeda), retinopatía diabética, en particular, edema macular diabético (DME) o edema macular secundario a la oclusión de la vena retiniana (RVO).